Miraculins Announces Deal With Leading CLIA Laboratory

Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on
developing and commercializing diagnostic tests for unmet clinical needs is
pleased to announce that it has signed a letter of intent with Mount Sinai
Services ("MSS") which would allow MSS to acquire FDA regulated commercial
products known as Analyte Specific Reagents ("ASRs") in order to develop in
house clinical tests for Miraculins' growing pipeline of biomarkers. Under the
agreement, Miraculins will also retain MSS to provide laboratory and testing
services for future clinical trials and regulatory clearance or approval studies
involving other products that Miraculins may seek to develop.


MSS, based in Toronto, Ontario, Canada, is a leading laboratory provider of
specialty services to the North American market offering a number of established
and custom developed analytical assays. In addition, MSS has a growing
reputation as a leader in the provision of novel innovative assays being one of
a small number of labs to offer the K-ras Mutation Detection Assay, which has
been shown in clinical studies to be an important tool in determining treatment
options for patients with metastatic colorectal cancer.


"Working with innovative partners like Miraculins is a key component of the MSS
business plan and this relationship will allow us to be one of the first to
offer our customers the latest assays to detect new and novel markers in areas
of important clinical need," commented Kenneth P.H. Pritzker M.D. FRCPC,
Managing Director of Mount Sinai Services. "We have reviewed Miraculins' new
strategy for advancing novel diagnostic assays to market and we are looking
forward to developing a number of exciting and innovative tests throughout the
life of our relationship."


"We are very pleased to have MSS agree to be the first CLIA laboratory to work
with Miraculins on its ASR strategy. In addition, as Miraculins acquires full
regulatory approval for any tests we independently develop, MSS will be a
natural part of our distribution plan," stated Christopher J. Moreau president
and CEO of Miraculins. "Access to the end-user market is critical to both our
new business strategy and the longer term adoption of our tests. Perhaps just as
important, Dr. Pritzker is a leading pathologist and a member of a critical
demographic for our products. We are excited by his interest in our technology
and his confidence in Miraculins."


Miraculins' growing pipeline of products includes reagents for the detection of
prostate cancer antigens. The Company is currently developing reagents for the
detection of PSP94 and a fragment of Vitronectin (P2V(TM)) and recently
announced that it would be in a position to begin offering a research use only
kit for the detection of PSP94 in research settings, in the near term.


The Company has also secured a term sheet with Mount Sinai Hospital that will
see it acquire a portfolio of biomarkers for use in developing diagnostic assays
for the early detection of preeclampsia, a disease of growing incidence and the
leading cause of maternal and prenatal deaths worldwide. Miraculins is also
developing an ASR strategy for these preeclampsia markers.


Furthermore, Miraculins is in various stages of licensing discussions with a
number of institutions in regards to a number of additional promising markers.


"This is an important relationship for Miraculins, as it allows us vertical
access on the supply chain as we advance our biomarkers, antibodies and
reagents", said Mr. Moreau.


About Mount Sinai Services

Mount Sinai Services (MSS) provides an extensive set of custom laboratory
research services for researchers, pharmaceutical companies and other industry
partners, including research & development (R&D) for diagnostic assays, new
platforms and medical devices.


MSS complies with the Good Laboratory Practice (GLP) principles for every
project where GLP is required. The facilities of Mount Sinai Services are
audited by FDA and private regulatory agencies. MSS utilizes Mount Sinai
Hospital labs which are accredited by the Ontario Laboratory Accreditation (OLA)
program and the College of American Pathologists which confers deemed CLIA
status.


About Kenneth P.H. Pritzker M.D. FRCPC

Dr. Kenneth Pritzker is the Managing Director of Mount Sinai Services;
Pathologist at Mount Sinai Hospital; and Professor, Laboratory Medicine and
Patholobiology at the University of Toronto. Dr. Pritzker has extensive interest
in laboratory organization and management directed towards advancing the
practice of pathology and laboratory medicine in academic medical centres, as
well as networking with community laboratories.


In addition, Dr. Pritzker acts as consultant in the areas of lab genetics,
strategic and operational advice for health care institutions and biotechnology
corporations. He also provides consultant services for preclinical and clinical
trials involving drugs and/or biomaterials, in cancer, articular/skeletal and
vascular applications.


To date, Dr. Pritzker has been author/co-author of 224 scientific papers and 15
book chapters. His areas of special research interest are bone and joint
diseases, particularly osteoarthritis, calcium pyrophosphate dihydrate crystal
deposition disease, osteoporosis and osteonecrosis.


About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on non-invasive
tests for unmet clinical needs. Miraculins is bridging the gap between
commercially available diagnostic tests and research conducted at leading
research institutions around the world.


Through an internal biomarker discovery research program, Miraculins has
advanced its prostate cancer diagnostic technology to the development stage. The
Company's lead product in development, P2V(TM), is a simple urine test intended
to be used as a pre-biopsy screen to eliminate a number of men who would
otherwise undergo unnecessary prostate biopsy surgery.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Miraculins' early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Miraculins' filings with Canadian securities regulatory
authorities, as well as Miraculins' ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release. Miraculins cautions
that the foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking statements to make
decisions with respect to Miraculins investors and others should carefully
consider the foregoing factors and other uncertainties and potential events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Miraculins
cannot provide assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to update or
revise any forward-looking statement.